MX2014015557A - Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada. - Google Patents
Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.Info
- Publication number
- MX2014015557A MX2014015557A MX2014015557A MX2014015557A MX2014015557A MX 2014015557 A MX2014015557 A MX 2014015557A MX 2014015557 A MX2014015557 A MX 2014015557A MX 2014015557 A MX2014015557 A MX 2014015557A MX 2014015557 A MX2014015557 A MX 2014015557A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor ligand
- conjugates
- altered
- region
- effector function
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Se reporta en la presente un polipéptido de fusión de región Fc o conjugado de región Fc que comprende uno a cuatro polipéptidos de ligando receptor de incretina y una región Fc humana variante con una mutación del residuo de aminoácido en la posición 329 y por lo menos una mutación adicional de por lo menos un aminoácido seleccionado del grupo que comprende residuos de aminoácido en las posiciones 228, 233, 234, 235, 236, 237, 297, 318, 320, 322 y 331 a un residuo diferente, en donde los residuos en la región Fc se numeran de acuerdo con el índice EU de Kabat y su uso como un medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662576P | 2012-06-21 | 2012-06-21 | |
PCT/US2013/046230 WO2013192131A1 (en) | 2012-06-21 | 2013-06-18 | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014015557A true MX2014015557A (es) | 2015-02-24 |
Family
ID=48626643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014015557A MX2014015557A (es) | 2012-06-21 | 2013-06-18 | Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140051834A1 (es) |
EP (1) | EP2863954A1 (es) |
JP (1) | JP2015531748A (es) |
KR (1) | KR20150023826A (es) |
CN (1) | CN104582736A (es) |
AR (1) | AR091476A1 (es) |
CA (1) | CA2877363A1 (es) |
HK (1) | HK1209034A1 (es) |
MX (1) | MX2014015557A (es) |
RU (1) | RU2015101699A (es) |
TW (1) | TW201402611A (es) |
WO (1) | WO2013192131A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG176858A1 (en) | 2009-06-16 | 2012-02-28 | Univ Indiana Res & Tech Corp | Gip receptor-active glucagon compounds |
GEP20176629B (en) | 2011-06-22 | 2017-02-27 | Indiana Unversity Research And Tech Corporation | Glucagon/glp-1 receptor co-agonists |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
NZ744257A (en) | 2011-06-28 | 2022-10-28 | Inhibrx Inc | Serpin fusion polypeptides and methods of use thereof |
WO2015035419A1 (en) * | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
EP3082847A1 (en) | 2013-12-20 | 2016-10-26 | Indiana University Research and Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
EP4299595A3 (en) | 2014-05-02 | 2024-03-13 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
BR112017008525A2 (pt) * | 2014-10-27 | 2018-01-30 | Inhibrx Lp | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. |
EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
WO2016131893A1 (en) * | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
CN108699125B (zh) * | 2015-12-31 | 2022-10-28 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂 |
EA201891990A1 (ru) * | 2016-03-04 | 2019-04-30 | Шайр Хьюман Дженетик Терапиз, Инк. | Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна |
KR102635635B1 (ko) | 2016-05-23 | 2024-02-14 | 모멘타 파머슈티컬스 인코포레이티드 | 유전자 조작 Fc 작제물에 관한 조성물 및 방법 |
TW201829463A (zh) * | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
CN117886928A (zh) | 2017-01-06 | 2024-04-16 | 动量制药公司 | 与经工程改造的Fc构建体相关的组合物和方法 |
CN107188953B (zh) * | 2017-07-11 | 2020-04-28 | 中国农业科学院北京畜牧兽医研究所 | 胰高血糖素样肽-1类似物及其用途 |
KR102668688B1 (ko) | 2018-07-23 | 2024-05-24 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
CN110964116A (zh) * | 2018-09-26 | 2020-04-07 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc融合蛋白及其缀合物 |
CN111217915B (zh) * | 2019-01-08 | 2021-05-14 | 东莞太力生物工程有限公司 | GLP-1类似物Fc融合多肽及其应用 |
KR102661468B1 (ko) | 2019-02-15 | 2024-04-30 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 전자 장치 |
WO2020172072A1 (en) * | 2019-02-21 | 2020-08-27 | The General Hospital Corporation | Glycoengineering immunoglobulin e |
KR20210059153A (ko) | 2019-11-14 | 2021-05-25 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 장치 |
CN113150172B (zh) * | 2021-04-28 | 2023-09-22 | 中国药科大学 | Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用 |
IL309067A (en) * | 2021-06-09 | 2024-02-01 | Scripps Research Inst | Long-range dual GIP/GLP-1 peptide conjugates and methods of use |
CN115521368A (zh) * | 2021-06-25 | 2022-12-27 | 江苏鸿永医药技术有限公司 | 毒蜥外泌肽-4衍生物 |
WO2023030444A1 (zh) * | 2021-09-02 | 2023-03-09 | 广东东阳光药业有限公司 | Glp-1/gip双靶多肽、融合蛋白及其应用 |
WO2023109928A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海宝济药业有限公司 | 抗免疫球蛋白降解酶酶切的Fc变体 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
DE60032331T2 (de) | 1999-01-14 | 2007-06-21 | Amylin Pharmaceuticals, Inc., San Diego | Exendine zur glucagon suppression |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR101077001B1 (ko) * | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
EA003922B1 (ru) | 1999-05-17 | 2003-10-30 | Конджачем, Инк. | Продолжительно действующие инсулинотропные пептиды |
US6514500B1 (en) | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
AU2003248370A1 (en) | 2002-02-27 | 2003-09-09 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
AU2003239478A1 (en) | 2002-06-04 | 2003-12-22 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
EP2345671B8 (en) | 2002-09-27 | 2023-01-11 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
ES2831379T3 (es) | 2003-10-09 | 2021-06-08 | Ambrx Inc | Derivados poliméricos para la modificación selectiva de proteínas |
ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
NZ548256A (en) | 2004-02-02 | 2010-02-26 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
KR20070039593A (ko) * | 2004-07-21 | 2007-04-12 | 암브룩스, 인코포레이티드 | 비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드 |
ZA200700359B (en) * | 2004-07-21 | 2008-12-31 | Ambrx Inc | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
EP1817340B1 (en) | 2004-11-12 | 2012-05-16 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US20060275282A1 (en) | 2005-01-12 | 2006-12-07 | Xencor, Inc. | Antibodies and Fc fusion proteins with altered immunogenicity |
US20090181037A1 (en) * | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
KR101666229B1 (ko) | 2008-02-08 | 2016-10-14 | 메디뮨 엘엘씨 | Fc 리간드 친화성이 감소된 항-IFNAR1 항체 |
EP2300037B1 (en) * | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
PE20100056A1 (es) | 2008-06-17 | 2010-01-26 | Univ Indiana Res & Tech Corp | Analogos de glucagon como agonistas gip |
US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8551946B2 (en) * | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
WO2011109784A1 (en) | 2010-03-05 | 2011-09-09 | Conjuchem, Llc | Formulation of insulinotropic peptide conjugates |
-
2013
- 2013-06-18 EP EP13736683.7A patent/EP2863954A1/en not_active Withdrawn
- 2013-06-18 RU RU2015101699A patent/RU2015101699A/ru not_active Application Discontinuation
- 2013-06-18 TW TW102121604A patent/TW201402611A/zh unknown
- 2013-06-18 CA CA2877363A patent/CA2877363A1/en not_active Abandoned
- 2013-06-18 WO PCT/US2013/046230 patent/WO2013192131A1/en active Application Filing
- 2013-06-18 JP JP2015518507A patent/JP2015531748A/ja not_active Abandoned
- 2013-06-18 CN CN201380043237.1A patent/CN104582736A/zh active Pending
- 2013-06-18 AR ARP130102141 patent/AR091476A1/es unknown
- 2013-06-18 MX MX2014015557A patent/MX2014015557A/es unknown
- 2013-06-18 KR KR20157001545A patent/KR20150023826A/ko not_active Application Discontinuation
- 2013-06-18 US US13/920,190 patent/US20140051834A1/en not_active Abandoned
-
2015
- 2015-10-05 HK HK15109708.7A patent/HK1209034A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2863954A1 (en) | 2015-04-29 |
TW201402611A (zh) | 2014-01-16 |
JP2015531748A (ja) | 2015-11-05 |
KR20150023826A (ko) | 2015-03-05 |
AR091476A1 (es) | 2015-02-04 |
US20140051834A1 (en) | 2014-02-20 |
CA2877363A1 (en) | 2013-12-27 |
RU2015101699A (ru) | 2016-08-10 |
WO2013192131A1 (en) | 2013-12-27 |
CN104582736A (zh) | 2015-04-29 |
HK1209034A1 (en) | 2016-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014015557A (es) | Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada. | |
NZ630484A (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
NZ600709A (en) | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof | |
CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
SG10201805411YA (en) | Chimeric antigen receptors | |
BR112014019901A2 (pt) | proteínas de fator viii recombinante | |
IN2014MN01642A (es) | ||
NZ611108A (en) | Methods of treating fgf21-associated disorders | |
JP2014530253A5 (es) | ||
WO2014150600A3 (en) | Modified toxins | |
PL2919801T3 (pl) | Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu | |
MY160995A (en) | Polypeptides with permease activity | |
MX2013007067A (es) | Anticuerpos anti-il-18 y sus usos. | |
GEP201706773B (en) | Cx3cr1-binding polypeptides | |
EA033007B1 (ru) | ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ | |
UA115436C2 (uk) | Протираковий злитий протеїн | |
MX339203B (es) | Proteina de fusion anticancer. | |
IL232867B (en) | Amyloid-binding polypeptide and chimeric protein containing it, pharmaceutical preparations containing the polypeptide or chimeric protein, methods for their preparation and uses | |
MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
HK1221163A1 (zh) | 融合多肽的替代配方 | |
EA201591609A1 (ru) | Варианты альфа-амилазы | |
PH12015501796B1 (en) | IL-1á INHIBITOR COMPOSITION AND USE THEREOF | |
WO2012174397A3 (en) | Anti-inflammatory pharmaceutical products | |
MX343589B (es) | Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. | |
SG10201803999UA (en) | Recombinant factor viii formulations |